ACHV
Neutral signalScored 2026-08-22 Drivers: fundamentals. Moteurs : fondamentaux.
Research, not advice.
À propos
Achieve Life Sciences, Inc.
- Nom
- Achieve Life Sciences, Inc.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $667.8M
- Employés
- 28
- PDG
- Andrew D. Goldberg
- Site web
- https://www.achievelifesciences.com
- Marché
- QNTM
Achieve Life Sciences, Inc. operates as a clinical-stage pharmaceutical firm, concentrating on the development and market introduction of cytisinicline. This compound is aimed at assisting with smoking cessation and nicotine dependence, with commercial activities spanning Canada, the United States, and the United Kingdom. Cytisinicline is a naturally occurring alkaloid, which functions by engaging with nicotine receptors in the brain to lessen the intensity of nicotine withdrawal symptoms. The company holds licensing agreements with Sopharma AD and the University of Bristol. Its corporate headquarters are located in Vancouver, Canada.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 20 626 titres (~175 176,62 $ US)
- Insiders
- Stewart Richard Alistair
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$175,177
Avg sell (VWAP, 90d window) $8.49 vs last close —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- 2026-08-19
- Last synced
-
2026-08-25 17:08:49
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-08-19 | Stewart Richard Alistair | Sell · S | 20,626 | $8.49 | $175,177 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Neutral signalScored 2026-08-22 Drivers: fundamentals. Moteurs : fondamentaux.
ACHV presents a severely distressed financial profile — zero revenue, interest coverage of -67.0, and complete dependence on external financing — which overwhelms the moderate positive catalyst from the $354M private…
The first sentence of the analysis written for ACHV on 2026-08-22 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Neutral signal
Drivers: fundamentals. Moteurs : fondamentaux.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Supports a bullish reading. Current ratio 4.39 · operating margin 0.0%
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebitda Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Net Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Current Ratio | 4.392 | 5.457 | 0.816 | 1.265 | 9.801 | |
| Quick Ratio | 4.392 | 5.457 | 0.816 | 1.265 | 9.801 | |
| Solvency Ratio | -2.684 | -2.233 | -1.421 | -1.944 | -1.690 | |
| Cash Ratio | 2.304 | 1.906 | 0.747 | 1.145 | 9.455 | |
| Price To Earnings Ratio | -3.976 | -2.839 | -2.747 | -0.620 | -1.921 | |
| Price To Earnings Growth Ratio | -4.930 | 0.164 | 0.044 | 0.251 | 0.077 | |
| Forward Price To Earnings Growth Ratio | -4.930 | 0.164 | 0.044 | 0.251 | 0.077 | |
| Price To Earnings Diluted Ratio | -3.976 | -2.839 | -2.747 | -0.620 | -1.921 | |
| Price To Earnings Diluted Growth Ratio | -4.930 | 0.164 | 0.044 | 0.251 | 0.077 | |
| Price To Book Ratio | 10.069 | 5.402 | -56.415 | 3.126 | 2.253 | |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Price To Free Cash Flow Ratio | -4.380 | -3.792 | -3.334 | -0.691 | -2.146 | |
| Price To Operating Cash Flow Ratio | -4.380 | -3.792 | -3.337 | -0.691 | -2.146 | |
| Debt To Assets Ratio | 0.358 | 0.258 | 0.864 | 0.540 | 0.316 | |
| Debt To Equity Ratio | 0.695 | 0.476 | -11.555 | 1.951 | 0.535 | |
| Debt To Capital Ratio | 0.410 | 0.323 | 1.095 | 0.661 | 0.348 | |
| Long Term Debt To Capital Ratio | 0.342 | 0.320 | 0.000 | 0.000 | 0.347 | |
| Financial Leverage Ratio | 1.942 | 1.849 | -13.378 | 3.610 | 1.694 | |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Ratio | -5.446 | -4.455 | -1.176 | -1.739 | -6.470 | |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | 1.000 | 1.001 | 1.000 | 1.000 | |
| Debt Service Coverage Ratio | -11.851 | -17.164 | -1.370 | -2.258 | 0.000 | |
| Interest Coverage Ratio | -67.009 | -17.922 | -9.551 | -22.806 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | -13.354 | 0.000 | -1.469 | -2.338 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -3.308 | -2.990 | -1.463 | -2.319 | -1.964 | |
| Capital Expenditure Coverage Ratio | -16,488.333 | 0.000 | -1,165.667 | 0.000 | 0.000 | |
| Dividend Paid And Capex Coverage Ratio | -16,488.333 | 0.000 | -1,165.667 | 0.000 | 0.000 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -3.931 | -2.943 | -3.100 | -0.432 | -1.068 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% |
| Ebit Margin | 0.0% | 0.0% | 0.0% |
| Ebitda Margin | 0.0% | 0.0% | 0.0% |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% |
| Net Profit Margin | 0.0% | 0.0% | 0.0% |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% |
| Current Ratio | 4.392 | ▼-1.065 | ▲0.046 |
| Quick Ratio | 4.392 | ▼-1.065 | ▲0.046 |
| Solvency Ratio | -2.684 | ▼-0.452 | ▼-0.690 |
| Cash Ratio | 2.304 | ▲0.399 | ▼-0.807 |
| Price To Earnings Ratio | -3.976 | ▼-1.137 | ▼-1.556 |
| Price To Earnings Growth Ratio | -4.930 | ▼-5.094 | ▼-4.051 |
| Forward Price To Earnings Growth Ratio | -4.930 | ▼-5.094 | ▼-4.051 |
| Price To Earnings Diluted Ratio | -3.976 | ▼-1.137 | ▼-1.556 |
| Price To Earnings Diluted Growth Ratio | -4.930 | ▼-5.094 | ▼-4.051 |
| Price To Book Ratio | 10.069 | ▲4.667 | ▲17.182 |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 |
| Price To Free Cash Flow Ratio | -4.380 | ▼-0.588 | ▼-1.511 |
| Price To Operating Cash Flow Ratio | -4.380 | ▼-0.588 | ▼-1.511 |
| Debt To Assets Ratio | 0.358 | ▲0.100 | ▼-0.109 |
| Debt To Equity Ratio | 0.695 | ▲0.218 | ▲2.275 |
| Debt To Capital Ratio | 0.410 | ▲0.087 | ▼-0.157 |
| Long Term Debt To Capital Ratio | 0.342 | ▲0.022 | ▲0.140 |
| Financial Leverage Ratio | 1.942 | ▲0.093 | ▲2.799 |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Ratio | -5.447 | ▼-0.991 | ▼-1.589 |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | ▲0.000 | ▼-0.000 |
| Debt Service Coverage Ratio | -11.851 | ▲5.314 | ▼-5.322 |
| Interest Coverage Ratio | -67.008 | ▼-49.087 | ▼-43.551 |
| Short Term Operating Cash Flow Coverage Ratio | -13.354 | ▼-13.354 | ▼-9.922 |
| Operating Cash Flow Coverage Ratio | -3.308 | ▼-0.318 | ▼-0.899 |
| Capital Expenditure Coverage Ratio | -16488.333 | ▼-16488.333 | ▼-12957.533 |
| Dividend Paid And Capex Coverage Ratio | -16488.333 | ▼-16488.333 | ▼-12957.533 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -3.931 | ▼-0.988 | ▼-1.636 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $216.7M | $112.9M | $81.7M | $26.0M | $63.2M | |
| Enterprise value | $210.7M | $110.1M | $82.9M | $17.4M | $35.1M | |
| EV / Sales | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | |
| EV / Op. cash flow | -4.26x | -3.70x | -3.39x | -0.46x | -1.19x | |
| EV / Free cash flow | -4.26x | -3.70x | -3.38x | -0.46x | -1.19x | |
| EV / EBITDA | -3.93x | -2.94x | -3.10x | -0.43x | -1.07x | |
| Net debt / EBITDA | 0.11x | 0.07x | -0.04x | 0.21x | 0.85x | |
| Current ratio | 4.39x | 5.46x | 0.82x | 1.26x | 9.80x | |
| Income quality | 0.91x | 0.75x | 0.82x | 0.89x | 0.89x | |
| Graham net-net | $0 | $1 | -$0 | $0 | $3 | |
| Tax burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 101.5% | 105.8% | 110.6% | 104.4% | 100.0% | |
| Working capital | $30.8M | $29.8M | -$3.8M | $5.7M | $40.0M | |
| Invested capital | $32.7M | $31.9M | -$1.5M | $8.3M | $42.8M | |
| Return on assets | -130.8% | -103.1% | -153.9% | -141.3% | -69.8% | |
| Operating ROA | -136.5% | -134.7% | -110.5% | -105.3% | -75.4% | |
| Return on tangible assets | -136.6% | -108.7% | -173.9% | -153.9% | -73.9% | |
| Return on equity | -254.0% | -190.6% | 2059.0% | -510.1% | -118.2% | |
| Return on invested capital | -150.5% | -122.1% | -178.3% | -166.5% | -76.9% | |
| Return on capital employed | -167.8% | -122.3% | 1889.7% | -487.3% | -77.0% | |
| Earnings yield | -25.2% | -35.3% | -36.5% | -163.2% | -52.5% | |
| Free cash flow yield | -22.8% | -26.4% | -30.0% | -144.8% | -46.6% | |
| Capex / Op. cash flow | -0.0% | 0.0% | -0.1% | 0.0% | 0.0% | |
| Capex / Depreciation | 1.3% | 0.0% | 9.2% | 0.0% | 0.0% | |
| Capex / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| SG&A / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Intangibles / Total assets | 4.3% | 5.2% | 11.5% | 8.2% | 5.6% | |
| Days sales outstanding | 0d | 0d | 0d | 0d | 0d | |
| Days payables outstanding | 1388d | 3108d | 0d | 0d | 0d | |
| Operating cycle | 0d | 0d | 0d | 0d | 0d | |
| Cash conversion cycle | -1388d | -3108d | 0d | 0d | 0d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+91.9%EV / Sales n/aEV / EBITDA ▼-33.6%EV / Op. cash flow ▼-0.561Earnings yield ▲+0.101
Profitability
Return on equity ▼-0.634Return on assets ▼-0.277Return on invested capital ▼-0.284Return on capital employed ▼-0.455Operating ROA ▼-0.018Income quality ▲+0.158Tax burden 0.000
Efficiency
Days sales outstanding n/aDays payables outstanding ▼-1720.118Operating cycle n/aCash conversion cycle ▲+1720.118Capex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▼-1.065Net debt / EBITDA ▲+0.037Working capital ▲+1022000.000Invested capital ▲+744000.000Intangibles / Total assets ▼-0.009
Change over 5 years
Valuation
Market cap ▲+243.0%EV / Sales n/aEV / EBITDA ▼-268.0%EV / Op. cash flow ▼-3.066Earnings yield ▲+0.273
Profitability
Return on equity ▼-1.357Return on assets ▼-0.610Return on invested capital ▼-0.736Return on capital employed ▼-0.908Operating ROA ▼-0.611Income quality ▲+0.017Tax burden 0.000
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▼-5.409Net debt / EBITDA ▼-0.740Working capital ▼-9237000.000Invested capital ▼-10127000.000Intangibles / Total assets ▼-0.014
Employee count
Peer market caps
Recent news
- 2026-08-11 Achieve Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Updates Closed a private placement of up to $354 million, with $180 million upfront and up to $174 million from warrants exercisable prior to and up to 20 trading days following FDA approval Strengthened organization with new Chief Executive Officer, experienced commercial, CMC, and quality leaders, along with six new appointments to the Board of Directors Anticipates potential FDA approval in the first half of 2027, followed by U.S. commercial launch SEATTLE and VANCOUVER, British Columbia, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve or the Company) (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced financial results for the second quarter of 2026 and provided business updates. “This quarter was about building Achieve to match the significant opportunity of cytisinicline,” said Andrew D.
- 2026-08-03 Achieve Life Sciences Appoints Ronald Dadino and Gloria Cosgrove to Lead CMC, Supply Chain, and Quality SEATTLE and VANCOUVER, British Columbia, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve or the Company) (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced the appointments of Ronald Dadino as Senior Vice President, Chemistry, Manufacturing and Controls (CMC) and Supply Chain, and Gloria Cosgrove as Senior Vice President, Quality. Both executives bring decades of leadership across pharmaceutical manufacturing, supply chain, and quality.
- 2026-07-31 Achieve Life Sciences Announced Granting of New Hire Inducement Awards SEATTLE and VANCOUVER, British Columbia, July 31, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced that Achieve''s board of directors approved stock option grants to purchase an aggregate of 1,190,000 shares of its common stock and restricted stock unit (“RSU”) awards covering an aggregate of 125,000 shares of its common stock for six new employees under Achieve''s 2024 Equity Inducement Plan. The stock options have an exercise price equal to the closing price of Achieve''s common stock on the grant date.
- 2026-07-19 Achieve Life Sciences (NASDAQ:ACHV) Shares Up 6.5% – Here’s Why Achieve Life Sciences, Inc. (NASDAQ: ACHV - Get Free Report) was up 6.5% during mid-day trading on Friday. The stock traded as high as $6.33 and last traded at $6.35. 209,257 shares were traded during trading, a decline of 84% from the average session volume of 1,329,049 shares. The stock had previously closed at $5.96.
- 2026-07-09 Achieve Life Sciences Stockholders Weigh Board Slate, Share Increase at Annual Meeting Achieve Life Sciences NASDAQ: ACHV held its 2026 Annual Meeting of Stockholders virtually, with Chief Executive Officer Andrew Goldberg serving as chairperson of the meeting. Goldberg called the meeting to order and said Erik Atkisson, the company''s Chief Legal Officer, would act as secretary and record the minutes.
- 2026-07-07 Achieve Life Sciences: Despite CRL, A Success Is Achieve-Able The last months were eventful for Achieve Life Sciences, sending the stock strongly down, but later to a new high for the year, implying optimism about the future path. Achieve is, in my view, a more derisked case now, thanks to successful financing, progress on shifting its supply chain, and new leadership. Despite the CRL, ACHV continues to advance. The denial was not drug-related, pointing towards a possible successful outcome in this story.
- 2026-06-29 Achieve Life Sciences Joins Russell 2000® Index SEATTLE and VANCOUVER, British Columbia, June 29, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve or the Company) (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced that it has been added to the Russell 2000® Index, effective June 26, 2026, as part of the Russell U.S. Indexes reconstitution. The Company is also a member of the Russell 3000® Index.
- 2026-06-23 Achieve Life Sciences: CRL Is Fixable, So I Remain Bullish Achieve Life Sciences remains a cytisinicline story, with very positive smoking-cessation data. This also gives cytisinicline some added optionality for vaping. The FDA''s CRL appears to be mostly about manufacturing and labeling issues. However, it''s not about a particular cytisinicline efficacy or safety problem. ACHV is currently targeting Q4 2026 resubmission and, assuming everything goes according to plan, it could receive approval by 1H2027.
- 2026-06-22 FDA Declines To Approve Achieve Life Sciences'' Smoking Cessation Drug; Q4 Resubmission Planned Achieve Life Sciences Inc. (NASDAQ:ACHV) on Monday received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for its New Drug Application seeking approval of cytisinicline, its investigational treatment for nicotine dependence.
- 2026-06-22 US FDA declines to approve Achieve Life Sciences'' smoking-cessation drug The U.S. Food and Drug Administration has declined to approve Achieve Life Sciences'' drug to treat nicotine dependence in adults, the company said on Monday.